Connect with us

Business

Fuel price hike deepens household anxiety | The Express Tribune

Published

on

Fuel price hike deepens household anxiety | The Express Tribune


Rs55/litre surge in petrol, diesel expected to push transport, food and production costs higher

Petrol rush. Photo: file


LAHORE:

The latest increase in petroleum prices has once again placed Pakistani household budgets under pressure, highlighting the fragile nature of economic stability in a country that relies heavily on imported fuel and gas.

Petrol is now priced at Rs321.17/litre and high-speed diesel at Rs335.86litre. The adjustment follows a sharp rise in international oil prices triggered by the United States and Israel’s illegitimate attack on Iran. For many Pakistanis, the development has revived a familiar sense of uncertainty. Just when inflation had begun showing signs of easing after months of tight monetary policies and government efforts to stabilise prices, the external shock has again raised fears about rising transportation costs, higher food prices and increasing electricity bills.

“We now largely feel that we might not be able to come out of this vicious circle,” said Muhammad Irfan, owner of a small grocery shop. He said fuel prices had remained relatively stable even though they were near historic highs, but the stability helped shopkeepers manage prices of other essential commodities. “The latest increase in fuel prices will ripple through the entire supply chain as whenever petrol goes up, everything else follows. The wholesalers increase their rates, transporters charge more, and then customers argue with us for higher prices. It becomes difficult for everyone,” he added.

Many middle-income Pakistanis believe the timing of the hike is particularly difficult as the country is currently observing the holy month of Ramazan. The festive season will soon follow with Eid for Muslims and Easter for the Christian community. “People were hoping this Eid would be a little easier after a tough year. Now I fear prices of flour, vegetables and meat will rise again,” said Bilal Ahmed, a ride-hailing driver. “Even buying clothes for children becomes a calculation.”

He said the fuel price adjustment directly affects his daily earnings. “I work nearly twelve hours a day, but every time petrol becomes expensive my income shrinks,” he said. “Customers are reluctant to pay higher fares while ride-hailing companies hesitate to increase fares for fear of losing customers. “But we cannot run our cars without fuel,” he said.

Blue-collar workers are feeling the pressure even more intensely. Sajid Mehmood, a construction labourer who commutes daily from the outskirts of the city, said higher diesel prices will quickly raise transport fares. “My wage has not increased in months, but the bus fare keeps rising,” he said. “By the end of the month there is almost nothing left.”

“The worst part is that we do not know if the fares will come down even if the fuel price hike reverses,” he said.

Economists say such developments highlight Pakistan’s vulnerability to global shocks. The Russia-Ukraine conflict triggered sharp increases in global commodity prices, while climate disasters such as floods placed additional strain on public finances and food supply chains. Political uncertainty and negotiations with international lenders have also complicated the country’s stabilisation efforts.

For many middle-class families, the problem is not only rising prices but also the unpredictability of financial planning. “Every time things start improving, some new crisis appears somewhere in the world,” said Sadia Sheikh, a schoolteacher and mother of two.

“You try to save money, plan your children’s education, maybe think about buying a small car, but then inflation returns and the plan collapses,” she said. “We know Pakistan imports oil and global prices affect us, but people also expect the government to prepare for these situations and strengthen internal systems,” she said.

The business community is also watching developments closely. Lahore Chamber of Commerce and Industry President Faheemur Rehman Saigol said, “Pakistan relies heavily on road-based freight and higher fuel prices will quickly move through supply chains, pushing up prices of food, construction materials and consumer goods. Exporters, already struggling with high energy tariffs and financing costs, may face additional pressure on competitiveness in international markets.

Small and medium-sized businesses are already feeling the pressure. Adnan Ali, who runs a garments workshop employing 12 workers, said rising fuel prices indirectly increase operational costs across the board. “Transporting raw material becomes expensive. The government already increased petrol prices by Rs8/litre and diesel by Rs5/litre on March 1. Electricity bills will eventually follow and we may have to increase the price of finished products,” he said.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Published

on

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial


Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA.

Spencer Grant | Universal Images Group | Getty Images

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration.

The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema, causing them to experience potentially life-threatening swelling attacks. Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver.

Intellia said the one-time treatment reduced attacks by 87% compared with a placebo, meeting the study’s main goal. Six months after treatment, 62% of patients were free from attacks and weren’t using other therapies, Intellia said.

The company described the safety and tolerability of the treatment as “favorable,” reporting the most common side effects were infusion-related reactions, headaches and fatigue. Analysts were closely watching safety in the trial since a patient in a separate trial of a different treatment from Intellia died. That patient developed a liver injury and ultimately died from septic shock following an ulcer, according to the company.

“When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we’ve had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you’re actually changing a gene that causes disease,” said Intellia CEO John Leonard.

The only FDA-approved Crispr-based medicine comes from Vertex Pharmaceuticals. Called Casgevy, the gene editing is done outside the body, or ex vivo. The process requires collecting a person’s blood cells, making the edits outside the body, then reinfusing them back into a patient. Intellia’s treatment, meanwhile, makes the edits inside the body, or in vivo.

Intellia said it has started a rolling application with the FDA and plans to complete the filing in the second half of this year. The company expects to launch the treatment in the U.S. in the first half of next year, if it’s approved.

If approved, Intellia’s treatment, lonvoguran ziclumeran, will compete with about a dozen other chronic drugs for HAE. Despite the allure of a one-time treatment, genetic medicines haven’t always been a commercial successes. BioMarin withdrew its gene therapy for Hemophilia A because of weak sales, for example.

Leonard said there are important differences between the two, like the fact that BioMarin’s therapy faced questions about how long the effects would last. In contrast, he said Intellia hasn’t seen a single case in almost six years where the effects diminished over time.

Despite the results, he’s reluctant to call Intellia’s treatment a functional cure.

“I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it’s permanent,” Leonard said. “And, as far as we can tell, we don’t have a single patient in this program or other program where there’s been any waning of the effect of what we did to the gene or the effect of what we’ve seen with the clinical aspects of the disease itself. So it’s pretty exciting.”

Clarification: This story has been updated to clarify that a patient in a separate trial of a different treatment from Intellia developed acute liver injury and ultimately died from septic shock following an ulcer.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Business

European flight prices are falling in short-term, Wizz Air boss says

Published

on

European flight prices are falling in short-term, Wizz Air boss says



While many airlines say they are raising prices due to high fuel costs, József Váradi says European airlines are trying to boost demand



Source link

Continue Reading

Business

Claire’s closes all 154 stores in UK and Ireland with loss of 1,300 jobs

Published

on

Claire’s closes all 154 stores in UK and Ireland with loss of 1,300 jobs



All of the chain’s standalone stores have stopped trading in the UK and Ireland.



Source link

Continue Reading

Trending